BREXAFEMME® (ibrexafungerp)
Vulvovaginal Candidiasis (VVC) and Recurrent VVC (rVVC)
ApprovedMarketed by GSK
Key Facts
Indication
Vulvovaginal Candidiasis (VVC) and Recurrent VVC (rVVC)
Phase
Approved
Status
Marketed by GSK
Company
About Scynexis
Scynexis has successfully transitioned to a commercial-stage biotech with the FDA approval of BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis, now exclusively licensed to GSK. Its core innovation is the fungerp platform, a first-in-class triterpenoid antifungal with a novel mechanism of action. The company's strategy involves leveraging partnerships for commercialization while advancing a next-generation pipeline, including SCY-247, to tackle life-threatening, drug-resistant invasive fungal infections and, following a recent acquisition, exploring new therapeutic areas like polycystic kidney disease.
View full company profile